Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

PEGylation Of Polylysine Dendrimers Improves Absorption And Lymphatic Targeting Following SC Administration In Rats.

L. M. Kaminskas, Jagannath Kota, Victoria M Mcleod, B. Kelly, Peter Karellas, C. J. Porter
Published 2009 · Chemistry, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Polylysine dendrimers have potential as highly flexible, biodegradable nanoparticular carriers that may also promote lymphatic transport. The current study was undertaken to determine the impact of PEGylation on the absorption and lymphatic transport of polylysine dendrimers modified by surface derivatisation with PEG (200, 570 or 2000Da) or 4-benzene sulphonate following SC or IV dosing. PEGylation led to the PEG(200) derived dendrimer being rapidly and completely absorbed into the blood after SC administration, however only 3% of the administered dose was recovered in pooled thoracic lymph over 30h. Increasing the PEG chain length led to a systematic decrease in absorption into the blood and an enhancement of the proportion recovered in the lymphatics (up to 29% over 30h). For the PEG(570) and PEG(2000) derived dendrimers, indirect access to the lymph via equilibration across the capillary beds also appeared to play a role in lymphatic targeting after both IV and SC dosing. In contrast, the anionic benzene sulphonate-capped dendrimer was not well absorbed from the SC injection site (26% bioavailability) into either the blood or the lymph. The data suggest that PEGylated poly-L-lysine dendrimers are well absorbed from SC injection sites and that the extent of lymphatic transport may be enhanced by increasing the size of the PEGylated dendrimer complex.
This paper references
10.1073/pnas.0607705103
A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas
C. Lee (2006)
10.1021/mp7001208
The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly l-lysine dendrimers.
L. M. Kaminskas (2008)
10.2337/diacare.13.9.911
Insulin Administration via Liposomes
R. S. Spangler (1990)
10.3109/02652049509087256
Lymphatic delivery and pharmacokinetics of methotrexate after intramuscular injection of differently charged liposome-entrapped methotrexate to rats.
C. K. Kim (1995)
10.1006/GYNO.1996.0184
Lymphatic spread of cervical cancer: an anatomical and pathological study based on 225 radical hysterectomies with systematic pelvic and aortic lymphadenectomy.
P. Benedetti-Panici (1996)
10.1021/MP060032E
Cationic poly-L-lysine dendrimers: pharmacokinetics, biodistribution, and evidence for metabolism and bioresorption after intravenous administration to rats.
B. Boyd (2006)
10.1002/JPS.21079
Dendrimers as drug carriers: applications in different routes of drug administration.
Y. Cheng (2008)
10.1023/A:1012117531448
Preparation of Biodegradable, Surface Engineered PLGA Nanospheres with Enhanced Lymphatic Drainage and Lymph Node Uptake
A. E. Hawley (2004)
10.1016/S0079-6107(96)00012-0
Advanced colloid-based systems for efficient delivery of drugs and diagnostic agents to the lymphatic tissues.
S. M. Moghimi (1996)
10.1016/S1359-6446(04)03276-3
Dendrimers and dendritic polymers in drug delivery.
E. Gillies (2005)
10.1007/BF01025246
Photon correlation spectroscopy of human IgG
T. Jøssang (1988)
10.1016/J.EJPB.2007.04.002
The role of the lymphatic system in subcutaneous absorption of macromolecules in the rat model.
L. Kagan (2007)
10.1038/362355A0
HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease
G. Pantaleo (1993)
10.1016/J.VASCN.2003.11.004
A stepwise surgical procedure to investigate the lymphatic transport of lipid-based oral drug formulations: Cannulation of the mesenteric and thoracic lymph ducts within the rat.
M. Boyd (2004)
10.1124/dmd.107.015669
Lymphatic Absorption of Subcutaneously Administered Proteins: Influence of Different Injection Sites on the Absorption of Darbepoetin Alfa Using a Sheep Model
Jagannath Kota (2007)
10.1016/j.ejmech.2007.12.021
The effect of dendrimers on the pharmacodynamic and pharmacokinetic behaviors of non-covalently or covalently attached drugs.
Y. Cheng (2008)
10.1038/nbt1171
Designing dendrimers for biological applications
C. C. Lee (2005)
10.1016/0014-5793(94)00351-3
Surface engineered nanospheres with enhanced drainage into lymphatics and uptake by macrophages of the regional lymph nodes
S. Moghimi (1994)
10.1016/S0168-3659(99)00246-1
Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo.
N. Malik (2000)
10.1038/362335a0
Cambrian sea water preserved as inclusions in marine low-magnesium calcite cement
W. J. Johnson (1993)
Plasma and lymph pharmacokinetics of recombinant human interleukin-2 and polyethylene glycol-modified interleukin-2 in pigs.
S. Chen (2000)
10.1021/MP049886U
Biological evaluation of polyester dendrimer: poly(ethylene oxide) "bow-tie" hybrids with tunable molecular weight and architecture.
E. Gillies (2005)
10.1248/BPB1978.11.700
Lymphatic transport of recombinant human tumor necrosis factor in rats.
K. Kojima (1988)
10.1016/J.BIOMATERIALS.2005.05.082
The effect of methoxy-PEG chain length and molecular architecture on lymph node targeting of immuno-PEG liposomes.
S. Moghimi (2006)
10.1016/S0169-409X(01)00154-5
Liposomes to target the lymphatics by subcutaneous administration.
C. Oussoren (2001)
10.1021/MP070047S
Impact of surface derivatization of poly-L-lysine dendrimers with anionic arylsulfonate or succinate groups on intravenous pharmacokinetics and disposition.
L. M. Kaminskas (2007)
10.1158/1535-7163.MCT-05-0325
Targeted delivery of methotrexate to epidermal growth factor receptor–positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates
G. Wu (2006)
10.1016/j.ejpb.2008.09.023
Dendrimers as versatile platform in drug delivery applications.
S. Svenson (2009)
10.20772/CANCERSCI1959.70.6_721
Tumor cell aggregation and mode of cancer spread in linitis plastica type of gastric carcinoma.
Y. Kodama (1979)
10.1023/A:1012145410859
Lymphatic Uptake and Biodistribution of Liposomes After Subcutaneous Injection: III. Influence of Surface Modification with Poly(ethyleneglycol)
C. Oussoren (2004)
10.1002/eji.200737984
Nanoparticles target distinct dendritic cell populations according to their size
V. Manolova (2008)
10.1016/S0169-409X(00)00121-6
Lymphatic targeting with nanoparticulate system.
Y. Nishioka (2001)
10.2174/138620707781662808
Dendrimer-based prodrugs: design, synthesis, screening and biological evaluation.
Y. Cheng (2007)
10.1023/A:1011081210142
Development of Systems for Targeting the Regional Lymph Nodes for Diagnostic Imaging: In Vivo Behaviour of Colloidal PEG-Coated Magnetite Nanospheres in the Rat Following Interstitial Administration
L. Illum (2004)
10.1517/17425247.4.5.495
Dendritic systems in drug delivery applications
N. Jain (2007)
10.1016/j.ddtec.2005.05.006
Subcutaneous drug delivery and the role of the lymphatics.
Danielle N. McLennan (2005)
10.1016/J.JCONREL.2005.12.019
Delivery of gadolinium-labeled nanoparticles to the sentinel lymph node: comparison of the sentinel node visualization and estimations of intra-nodal gadolinium concentration by the magnetic resonance imaging.
Hisataka Kobayashi (2006)
10.1016/S0005-2736(97)00275-7
Lymphatic uptake and biodistribution of liposomes after subcutaneous injection . IV. Fate of liposomes in regional lymph nodes.
C. Oussoren (1998)
10.1002/(SICI)1520-6017(200003)89:3<297::AID-JPS2>3.0.CO;2-P
Lymphatic transport of proteins after subcutaneous administration.
C. J. Porter (2000)
10.1002/(SICI)1097-0142(19971001)80:7<1188::AID-CNCR2>3.0.CO;2-H
Lymph node micrometastases from breast carcinoma
K. Dowlatshahi (1997)



This paper is referenced by
10.1021/acsami.6b05534
Maximizing the Supported Bilayer Phenomenon: Liposomes Comprised Exclusively of PEGylated Phospholipids for Enhanced Systemic and Lymphatic Delivery.
Matthew T. Haynes (2016)
10.1021/acs.nanolett.9b03483
Sugar-Nanocapsules Imprinted with Microbial Molecular Patterns for mRNA Vaccination.
Sejin Son (2020)
10.3923/RJNN.2011.60.74
Novel Modified Nanosystem Based Lymphatic Targeting
S. Saraf (2011)
10.1152/ajpgi.00340.2019
Organ-specific lymphatics play distinct roles in regulating HDL trafficking and composition.
Gracia Gracia (2020)
10.1016/j.nano.2016.03.002
Disposition and safety of inhaled biodegradable nanomedicines: Opportunities and challenges.
S. Haque (2016)
10.1016/j.ijpharm.2019.118456
Therapeutic delivery to the peritoneal lymphatics: current understanding, potential treatment benefits and future prospects.
Ali Sarfarazi (2019)
10.1016/J.COCHE.2014.11.003
Overcoming transport barriers for interstitial-, lymphatic-, and lymph node-targeted drug delivery.
S. N. Thomas (2015)
10.1016/j.addr.2019.08.009
Lymphatic changes in cancer and drug delivery to the lymphatics in solid tumors.
B. Cote (2019)
10.1038/s41401-020-0417-3
Nanoengineered targeting strategy for cancer immunotherapy
W. Yin (2020)
10.1021/mp2005966
Association of chemotherapeutic drugs with dendrimer nanocarriers: an assessment of the merits of covalent conjugation compared to noncovalent encapsulation.
L. M. Kaminskas (2012)
10.1155/2011/254095
High-Resolution Imaging of Dendrimers Used in Drug Delivery via Scanning Probe Microscopy
Lifang Shi (2011)
10.3390/POLYM6010179
Polyester Dendrimers: Smart Carriers for Drug Delivery
Amour K. Twibanire (2014)
10.1021/mp400464s
The lymphatic system plays a major role in the intravenous and subcutaneous pharmacokinetics of trastuzumab in rats.
Annette M Dahlberg (2014)
10.1016/j.ijpharm.2020.119021
Carboxyl-, sulfonyl-, and phosphate-terminal dendrimers as a nanoplatform with lymph node targeting.
Yasuaki Nishimoto (2020)
10.1016/J.JPHOTOCHEM.2010.11.015
Photophysical investigation of microenvironment in glycerol based dansylated polyether dendrons
Usharani Subuddhi (2011)
10.1016/j.jamcollsurg.2011.11.006
Nanoparticle migration and delivery of Paclitaxel to regional lymph nodes in a large animal model.
O. Khullar (2012)
10.1002/mabi.201000473
Highly efficient intracellular drug delivery with a negatively charged hyperbranched polysulfonamine.
Suyun Chen (2011)
10.2217/nnm.11.67
Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties.
L. M. Kaminskas (2011)
10.1201/9781315364513-10
Impact of physicochemical properties on dendrimer pharmacokinetics and biodistribution
O. Feeney (2016)
10.1007/978-1-4614-9434-8
Focal Controlled Drug Delivery
A. Domb (2014)
10.1016/j.jconrel.2018.02.003
Mechanism‐based pharmacokinetic (MBPK) models describe the complex plasma kinetics of three antiretrovirals delivered by a long‐acting anti‐HIV drug combination nanoparticle formulation
J. C. Kraft (2018)
10.1517/17425247.2013.771630
Nanopharmaceuticals to target antifilarials: a comprehensive review
M. Ali (2013)
10.4236/IJOC.2013.31006
Synthesis and Characterization of Luteinizing Hormone-Releasing Hormone (LHRH)-Functionalized Mini-Dendrimers
A. Rafiee (2013)
Conception, synthèse et caractérisation de nouvelles macromolécules branchées biocompatibles pour encapsuler des principes actifs hydrophobes
I. Elkin (2014)
10.1021/mp500531e
Methotrexate-conjugated PEGylated dendrimers show differential patterns of deposition and activity in tumor-burdened lymph nodes after intravenous and subcutaneous administration in rats.
L. M. Kaminskas (2015)
10.37285/ijpsn.2015.8.3.4
Recent Advances in Nanotechnology based Tubercular Chemotherapy
Sunil Khatak (2015)
10.1007/978-1-4614-9434-8_20
Delivery Systems for Lymphatic Targeting
I. Singh (2013)
10.1007/s11095-010-0339-8
Designing Dendrimers for Drug Delivery and Imaging: Pharmacokinetic Considerations
Wassana Wijagkanalan (2010)
10.1128/JVI.00386-20
Polyethylene Glycol 40-Modified Peptide with High Therapeutic Efficacy in Simian-Human Immunodeficiency Virus-Acutely Infected Rhesus Monkeys
Mingli Li (2020)
This thesis is based on following publications :
Muhammet S. Toprak (2010)
10.1016/j.jconrel.2013.03.006
PEGylation of interferon α2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases.
L. M. Kaminskas (2013)
10.1002/jps.22682
Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance.
L. M. Kaminskas (2011)
See more
Semantic Scholar Logo Some data provided by SemanticScholar